Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDURA XL vs HYTRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.
Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).
Benign prostatic hyperplasia (FDA-approved),Hypertension (FDA-approved)
Benign prostatic hyperplasia (BPH),Hypertension (as monotherapy or in combination with other antihypertensives)
4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.
Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.
15-22 hours in adults; terminal half-life is approximately 22 hours for extended-release formulation, allowing once-daily dosing. Half-life is prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life: 12–13 hours (range 10–15 h); clinical context: steady state achieved in 2–3 days; dose adjustment not required in renal impairment but caution in hepatic impairment.
Extensively metabolized in the liver via CYP3A4 and CYP2D6; undergoes O-demethylation and hydroxylation.
Extensively metabolized in the liver via demethylation and dehydrogenation; multiple metabolites are formed, some pharmacologically active. CYP450 enzymes involved include CYP3A4 and CYP2D6.
Primarily hepatic metabolism via CYP3A4, with ~63% of the dose excreted in feces as metabolites and ~9% in urine as unchanged drug. Renal elimination of active drug is minimal (<1%).
Renal: ~40% as metabolites, <1% unchanged; biliary/fecal: ~60% as metabolites; total clearance 6.4 L/h.
~98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
90–94% bound to albumin; free fraction 6–10%.
1.9-3.1 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle.
Vd: 3.9 L/kg (range 3.5–4.3 L/kg); large Vd indicates extensive tissue distribution, high affinity for vascular smooth muscle.
Oral extended-release: ~85% relative to immediate-release formulation, with minimal first-pass metabolism. Food does not significantly affect absorption.
Oral bioavailability: >90% (first-pass metabolism minimal); food does not affect absorption.
No dose adjustment required for renal impairment (GFR ≥30 m L/min). For GFR <30 m L/min, use with caution; no specific dose recommendation available.
No specific GFR-based dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), start at 2 mg once daily and titrate cautiously.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate (Child-Pugh A or B), initial dose 1 mg at bedtime, titrate cautiously; monitor for hypotension.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Not approved for use in children; safety and efficacy not established.
Initiate at 2 mg once daily with breakfast; titrate slowly to avoid orthostatic hypotension. Monitor blood pressure closely.
Initiate at 1 mg at bedtime to minimize orthostatic hypotension; titrate slowly. Elderly patients may experience increased sensitivity to hypotensive effects. Monitor blood pressure and renal function.
None.
None.
Orthostatic hypotension and syncope, especially with first dose or dose increase,Priapism (rare),Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery,Hepatic impairment: dose adjustment may be needed
Orthostatic hypotension and syncope, especially with first dose (first-dose effect); dose titration recommended.,Priapism (rare); advise patient to seek immediate medical attention if erection persists >4 hours.,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on alpha-1 blockers.,Use with caution in patients with renal impairment or hepatic impairment.,May cause dizziness, drowsiness, or blurred vision; caution when driving or operating machinery.
Hypersensitivity to doxazosin or any component,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Hypersensitivity to terazosin or any component of the formulation.,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) may increase risk of hypotension (relative contraindication; use with caution).
Avoid grapefruit and grapefruit juice as they may increase doxazosin concentrations. No other significant food interactions known. Alcohol may exacerbate hypotensive effects.
No significant food interactions. Avoid grapefruit juice as it may increase drug levels. Take with or without food. Limit alcohol intake as it may enhance orthostatic effects.
Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third trimesters: Potential for reduced placental perfusion due to alpha-blockade; avoid use unless benefit outweighs risk.
Terazosin (HYTRIN) is FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, terazosin was not teratogenic in rats or rabbits at doses up to 200 mg/kg/day (rat) and 75 mg/kg/day (rabbit), but delayed fetal ossification was observed. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
Unknown if excreted in human milk; M/P ratio not available. Caution advised; use only if clearly needed.
It is not known whether terazosin is excreted in human milk. The M/P ratio is unknown. Caution is advised when administered to a nursing woman; consider developmental and health benefits of breastfeeding along with mother's clinical need.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume. Use lowest effective dose and monitor clinical response.
No specific pharmacokinetic data in pregnancy. However, pregnancy may alter volume of distribution and hepatic clearance, potentially affecting drug levels. Dose adjustments may be needed based on clinical response and blood pressure monitoring. Start with lowest effective dose and titrate cautiously.
CARDURA XL (doxazosin extended-release) is an alpha-1 adrenergic blocker primarily used for benign prostatic hyperplasia (BPH). Its prolonged action reduces the risk of first-dose syncope compared to immediate-release. Do not crush or chew; swallow whole. Monitor blood pressure in patients also on antihypertensives due to additive hypotensive effects. Avoid use in patients with history of orthostatic hypotension or micturition syncope.
HYTRIN (terazosin) is an alpha-1 adrenergic blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope can occur; start with 1 mg at bedtime. Titrate slowly to avoid orthostatic hypotension. Monitor blood pressure 2-3 hours after initial dose and after dose increases. May cause intraoperative floppy iris syndrome (IFIS) in cataract surgery; notify ophthalmologist. Use with caution in patients with renal impairment. Can be used alone or with other antihypertensives.
Take exactly as prescribed, once daily with or without food. Swallow tablet whole, do not crush or chew.,Avoid grapefruit juice as it may alter drug levels.,Possible side effects include dizziness, fatigue, and nasal congestion. Rise slowly from sitting or lying to reduce fall risk.,May cause orthostatic hypotension especially after first dose or dose increase.,If you experience lightheadedness or fainting, contact your doctor.
Take the first dose at bedtime to minimize dizziness or fainting.,Avoid sudden standing or sitting up quickly to prevent orthostatic hypotension.,Report any prolonged erections lasting more than 4 hours immediately.,Avoid driving or hazardous activities until you know how the drug affects you.,Do not stop taking abruptly; consult doctor for gradual dose reduction.,Inform all healthcare providers, especially eye surgeons, that you are taking terazosin.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDURA XL vs HYTRIN, answered by our medical review team.
CARDURA XL is a Alpha-1 Blocker Antihypertensive that works by Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.. HYTRIN is a Alpha-1 Blocker that works by Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDURA XL and HYTRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDURA XL is: 4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.. The standard adult dose of HYTRIN is: Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDURA XL and HYTRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDURA XL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third tr. HYTRIN is classified as Category C. Terazosin (HYTRIN) is FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, terazosin was not teratogenic in rats or rabbits at do. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.